A 45-year-old woman from Mumbai with a history of poorly controlled type 2 diabetes mellitus presents with a 2-month history of cough, weight loss, and recurrent low-grade fever. Sputum smear microscopy shows acid-fast bacilli on Ziehl-Neelsen staining. She is started on standard four-drug anti-TB therapy (HRZE). After 2 weeks of treatment, her symptoms improve and sputum smear becomes negative. However, at the 2-month follow-up, her sputum smear becomes positive again despite reported good adherence. Repeat drug susceptibility testing shows resistance to isoniazid and rifampicin. Which of the following mechanisms is MOST likely responsible for the emergence of drug-resistant M. tuberculosis in this patient?

Explanation

## Drug-Resistant M. tuberculosis — Mechanism of Resistance Emergence ### The Natural History of Resistance **Key Point:** M. tuberculosis is a haploid organism with a relatively slow mutation rate (~10^−8 to 10^−9 per base pair per generation). However, within a large bacterial population (10^8–10^9 organisms in a cavity), spontaneous mutations conferring drug resistance occur naturally and are then **selected for** by continued antibiotic exposure. ### Isoniazid and Rifampicin Resistance Mechanisms | Drug | Gene(s) Affected | Mechanism | |------|------------------|----------| | **Isoniazid** | *katG*, *inhA* | Loss of catalase-peroxidase (KatG) prevents pro-drug activation; mutations in enoyl-ACP reductase (InhA) reduce drug binding | | **Rifampicin** | *rpoB* | Mutations in RNA polymerase β-subunit prevent drug binding to the enzyme | **High-Yield:** These are **chromosomal mutations**, not plasmid-mediated resistance. M. tuberculosis has a small, stable genome (~4.4 Mb) with minimal horizontal gene transfer capacity. ### Why Resistance Emerged in This Patient 1. **Pre-existing resistant mutants:** Within the patient's initial bacterial burden, a small subpopulation of organisms with *katG* and *rpoB* mutations likely existed at baseline (frequency ~10^−6 to 10^−7) 2. **Selection pressure:** Four-drug therapy killed the drug-susceptible majority, leaving resistant mutants to expand 3. **Inadequate initial drug levels or adherence gaps:** Even with reported "good adherence," suboptimal drug concentrations in certain lung compartments or brief lapses can allow resistant clones to proliferate 4. **Diabetes as a risk factor:** Poor glycemic control impairs immune function, allowing larger bacterial populations and higher mutation rates **Clinical Pearl:** The 2-month conversion from negative to positive sputum smear suggests **acquired drug resistance** (ADR) rather than primary drug-resistant TB (which would not show initial sputum conversion). This is the classic pattern of monotherapy-like selection when a single drug is under-dosed or when the patient has a subpopulation of resistant organisms that expand after susceptible organisms are killed. ### Why M. tuberculosis Resistance Is Chromosomal **Mnemonic:** **CHR** = **Ch**romosomal **R**esistance (not plasmid-mediated) - M. tuberculosis lacks plasmids (or has very rare, cryptic plasmids) - No integrons or transposons carrying resistance genes - Resistance emerges through point mutations in essential genes - This is why TB drug resistance is slower to develop than in organisms like *Pseudomonas* or *Acinetobacter* (which use plasmid-mediated resistance) ### Management Implications **Warning:** Once multidrug-resistant TB (MDR-TB; resistant to isoniazid and rifampicin) is confirmed, the patient must be switched to a longer, more complex regimen: - Fluoroquinolone (e.g., levofloxacin) - Bedaquiline (newer TB drug) - Linezolid - Pyrazinamide (if susceptible) - Duration: 20 months minimum **Key Point:** This case illustrates why directly observed therapy (DOT) and adequate drug levels are critical — they minimize the window during which resistant mutants can be selected.